Role: 1165

To apply for 'FCO/FD' role click 'here'

To apply for 'Sales & Marketing' role click 'here'

To apply for 'Logistics & Supply Chain' role click 'here'

Website

Investing Non-Executive Directors (Non-Exec) with backgrounds / experience in high growth start-up businesses in the herbal remedy market that uses functional ingredients to support healthy brain function and mental wellbeing. THEENK TEA is a modern response to the modern customers’ needs.

The company, based in London, was launched in 2019 after the founder was left with some nasty side effects from prescribed antidepressants.  She decided to harness the power of nature to create a holistic experience to support the mind on a daily basis.

THEENK TEA is looking to strengthen their Board with the appointment of three Investing Non-Executive Directors to contribute their knowledge, experience and networks to the growth of the company.

The Non-Executive Directors will be encouraged to become shareholders in the Company to align their interests with that of the existing Directors who are shareholders.

Business Concept: 

THEENK TEA is the first product of its kind on the market. It’s been developed to support one of the most important organs in the human body - the brain. THEENK TEA uses functional herbal ingredients to support the brain function throughout the challenges of everyday life. It’s designed to maintain balanced energy levels, improve focus, relieve stress and help achieve a good night’s sleep.

THEENK is a set of award-winning carefully selected blends of 12 powerful herbs designed by their experienced herbalist to support healthy brain function and mental wellbeing throughout challenges of various times of the day. Each box is packed with functional adaptogens, nootropics and gentle stimulants divided into 3 functional blends for mornings, afternoons and evenings. 

Market & Opportunity:

  • In 2020, the total spending on healthcare, wellness and fitness is forecast to reach £209 bn.
  • According to Hexa Research herbal remedy market has been valued at $71 bn in 2016 and is expected to significantly grow in upcoming years.
  • Global Apoptogenic Market has been valued at £8.11bn in 2020 and is expected to reach £17.9bn in 2030. Adaptogens and Nootropics are already very popular in the US, but still an emerging market in the UK. This has however been growing very quickly especially now during the pandemic.

 

Business Proposition: 

  • THEENK are looking to close net £180,000 of funding for a 12 month growth plan.
    • SEIS/EIS Assurance available
    • Total Equity offered 10% (i.e., 1.7% per £35,000 investment)
    • Use of funds: recruitment of a Sales Co-ordinator, a Social Media & PR Co-ordinator, Operations Manager (part time) and to invest in the website, marketing, product development and manufacturing.

 

Non-Executive Director Criteria:

  • Finance experienced CFO/FD with commercial fundraising
  • Sales & Marketing Executive
  • Logistics/supply chain experience

 

Closing date for applications: Tuesday, 30th November 2021

Success Stories